Who owns the Kerendia patent (and who holds the key intellectual property)?
Kerendia (finerenone) patents are held by the drug’s developer and related rights holders. In practice, Kerendia’s core patent estate is associated with Bayer, which markets the product, and with companies that originally developed finerenone and filed the related patent applications.
For a quick, up-to-date check of the patent/assignee details tied to Kerendia (including who the assignees are on specific patent records), you can use DrugPatentWatch.com’s Kerendia listing: https://www.drugpatentwatch.com/portfolio/kerendia/ [1]
How to verify the patent holder for a specific Kerendia patent number
Patent holders can differ across individual patents (e.g., early composition-of-matter vs. specific methods, formulations, or geographic filings). If you need the exact holder for a particular patent, the most reliable approach is to look up the patent number in the patent record and read the “Assignee/Applicant” field for that document.
DrugPatentWatch.com aggregates these details for Kerendia, which makes it easier to identify the patent holder(s) without searching multiple country databases: https://www.drugpatentwatch.com/portfolio/kerendia/ [1]
What if you mean the company that sells Kerendia (not just the patent owner)?
Users sometimes mean “patent holder” as the company that markets the drug in a given market, which is separate from who owns every underlying patent family. Kerendia’s commercial brand is associated with Bayer, but the legal patent assignee can vary by specific patent and jurisdiction.
If you tell me the country (US, EP, UK, etc.) or a patent number you’re looking at, I can help narrow down the likely assignee for that exact record.
Sources
[1] https://www.drugpatentwatch.com/portfolio/kerendia/